UVADEX Rx

Select the drug indication to add to your list

UVADEX

Leukemias, lymphomas, and other hematologic cancers
Only 4 drugs may be compared at once

Generic Name and Formulations:

Methoxsalen 20mcg/mL; sterile soln.

Company:

Therakos, Inc.

Select therapeutic use:

Indications for UVADEX:

Extracorporeal administration with the UVAR XTS or CELLEX Photopheresis System in the palliative treatment of skin manifestations of cutaneous T-cell lymphoma that is unresponsive to other forms of treatment.

Adult:

Consult UVAR XTS or CELLEX Photopheresis System Operator's Manual before administering. Give on 2 consecutive days every 4 weeks for minimum of 7 treatment cycles (6 months). Calculate dose per treatment based on treatment volume: Dose (mL) = treatment volume x 0.017. Accelerated treatment schedule: see full labeling.

Children:

Not established.

Contraindications:

Idiosyncratic reactions to psoralen compounds. History of light sensitive disease. Lupus erythematosus. Porphyria cutanea tarda. Erythropoietic protoporphyria. Variegate porphyria. Xeroderma pigmentosum. Albinism. Aphakia.

Warnings/Precautions:

Exposure to sun or UV light may cause actinic degeneration, skin burning, cataracts; wear UVA-absorbing, wrap-around sunglasses and cover exposed skin (or use sunblock: SPF ≥15) for 24hrs after treatment. Basal cell carcinomas; monitor. Possible thromboembolic events in treatment of graft-versus-host disease (not approved use). Pregnancy (Cat.D); avoid. Nursing mothers.

Interactions:

Increased photosensitivity with anthralin, coal tar, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides, sulfonamides, tetracyclines, thiazides, certain organic staining dyes (eg, methylene blue, toluidine blue, rose bengal, methyl orange).

Pharmacological Class:

Photoactive agent.

Adverse Reactions:

Hypotension secondary to changes in extracorporeal volume.

How Supplied:

Single-use vials (10mL)—12